BOSTON, Mass., May 14, 2026 — Byongen Therapeutics (“Byongen”), a biotechnology company specializing in next-generation AAV vector engineering, today presented non-human primate (NHP) validation data ...

BEIJING, April 30, 2026 — Byongen Therapeutics, an innovative biotechnology company dedicated to next-generation viral vector engineering, today announced that it has been selected to present one oral...

NEW ORLEANS, LA – Byongen Therapeutics, a biotechnology company specializing in next-generation viral vector engineering, today announced that it will present the latest breakthroughs from its prop...

BEIJING, February 19, 2025 — Beijing Byongen Therapeutics Co., Ltd. (Byongen Therapeutics) and Beijing Genecradle Therapeutics Technology Co., Ltd. (Genecradle Therapeutics) today announced...

BEIJING, January 1, 2025 — Beijing Byongen Therapeutics Co., Ltd. (Byongen Therapeutics) is proud to announce that it has been officially recognized as a "Beijing Innovative Small and Medium-s...